Table 2.

Effect of BAY 41-2272 on the viability of PBM or THP-1 cells

		MTT reduction (% control)
Cells	Treatment	30 min	120 min
PBM	1.0 µM BAY 41-2272	95.32 ± 5.41	104.30 ± 2.10
	3.0 µM BAY 41-2272	98.62 ± 2.35	102.80 ± 0.44
	10.0 µM BAY 41-2272	98.01 ± 3.34	99.12 ± 3.00
	3.0 µM BAY 41-2272 + 100 U·mL−1 IFN-γ	72 ± 1.45	44 ± 2.65*
	0.7% DMSO	98.75 ± 2.87	96.07 ± 3.05
	30 nM PMA	94.03 ± 3.32	92.13 ± 2.72
	300 nM PMA	92.10 ± 0.38	68.45 ± 2.62*
THP-1	1.0 µM BAY 41-2272	102.00 ± 5.20	101.40 ± 1.96
	3.0 µM BAY 41-2272	98.05 ± 0.65	106.85 ± 2.62
	10.0 µM BAY 41-2272	97.98 ± 3.06	105.78 ± 1.70
	3.0 µM BAY 41-2272 + 100 U·mL−1 IFN-γ	78 ± 2.31	56 ± 0.20*
	0.7% DMSO	106.44 ± 2.07	102.05 ± 4.17
	30 nM PMA	98.45 ± 2.65	94.76 ± 3.10
	300 nM PMA	94.65 ± 2.54	84.33 ± 2.23*

Human PBM or THP-1 cell suspensions (2 × 10⁶ cells·mL⁻¹) were incubated at 37°C for 30 min or 120 min with BAY 41-2272 (1.0–10.0 µM) or PMA (30 or 300 nM). Each experiment was carried out in quintuplicate (n= 5).

The results are expressed as MTT reduction (% control, mean ± SEM).

^*anova, P < 0.05.